Q-Line Biotech (NSE:QLINE) Total Debt per Share: ₹71.29 (As of Mar. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:QLINE Q-Line Biotech Ltd NSE:QLINE
14 GF Score
Price ₹531.80
! 2 Warning Signs
View Full Analysis

What is Q-Line Biotech Total Debt per Share?

Q-Line Biotech NSE:QLINE -1.12% 14 Total Debt per Share is ₹71.29 as of Mar. 2025. GuruFocus rates NSE:QLINE with a GF Score™ of 14/100. The stock has 2 warning signs investors should review.

₹71.29 (As of Mar. 2025)

Total Debt per Share is calculated as total debt divided by Shares Outstanding (EOP). Total debt is calculated as Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Q-Line Biotech's Total Debt Per Share for the quarter that ended in Mar. 2025 was ₹71.29.

Q-Line Biotech Total Debt per Share Historical Data

* Premium members only.

The historical data trend for Q-Line Biotech's Total Debt per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Q-Line Biotech Total Debt per Share Chart

Q-Line Biotech Annual Data
Trend Mar23 Mar24 Mar25
Total Debt per Share
31.57 41.54 71.29

Q-Line Biotech Semi-Annual Data
Mar23 Mar24 Mar25
Total Debt per Share 31.57 41.54 71.29
NSE:QLINE
14GF Score
Q-Line Biotech Ltd NSE:QLINE
Total Debt per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Q-Line Biotech Total Debt per Share Calculation

Q-Line Biotech's Total Debt Per Share for the fiscal year that ended in Mar. 2025 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(824+839)/23
=71.29

Q-Line Biotech's Total Debt Per Share for the quarter that ended in Mar. 2025 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(824+839)/23
=71.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Debt per Share →
What does a Total Debt per Share of ₹71.29 mean?
Q-Line Biotech (NSE:QLINE) has a Total Debt per Share of ₹71.29 as of Mar. 2025. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on Q-Line Biotech and its competitors.
Is Q-Line Biotech's Total Debt per Share too high?
Q-Line Biotech's current Total Debt per Share is ₹71.29. Overall, Q-Line Biotech has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Q-Line Biotech's Total Debt per Share compare to ABT and SYK?
Q-Line Biotech's Total Debt per Share of ₹71.29 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Debt per Share for a Medical Devices & Instruments company?
A good Total Debt per Share depends on the Medical Devices & Instruments industry context. However, Total Debt per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Debt per Share mean?
A high Total Debt per Share can signal that a stock is expensive relative to its fundamentals. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on Q-Line Biotech and its competitors. Q-Line Biotech's current Total Debt per Share is ₹71.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q-Line Biotech stock overvalued right now?
Q-Line Biotech (NSE:QLINE) has a current Total Debt per Share of ₹71.29. The current Total Debt per Share is ₹71.29. Q-Line Biotech's overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Debt per Share calculated?
Total Debt per Share is calculated from a company's financial statements. For Q-Line Biotech (NSE:QLINE), the current Total Debt per Share is ₹71.29 as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Q-Line Biotech Business Description

Address Kanpur Road Adjacent Transport Nagar Metro Station, 298-281, Transport Nagar, Lucknow, UP, IND, 226012
Q-Line Biotech Ltd is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs directly or through its distributors majorly to diagnostic service providers, hospitals and medical colleges. It is engaged in Manufacturing and Trading into Biochemistry Regnant, Instruments and Consumables. The majority of revenue is derived from the Manufacturing segment.
14GF Score

Get the complete analysis for NSE:QLINE

Total Debt per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹531.80
Price